Evidence map›Paper›PMID 42065053›Full record

ArticleOncology research2026

MYO18A Expression is a Prognostic Factor for Progression-Free Survival in Grade 4 Adult gliomas. Preliminary Report.

Aleksander Strąk, Ludmiła Grzybowska-Szatkowska, Paweł Cisek, Marta Ostrowska-Leśko, Jarosław Dudka, Joanna Kubik, Jacek Osuchowski, Paweł Szmygin, Bożena Jarosz, Andrzej Krajka and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aleksander StrąkDepartment of Radiotherapy, Medical University of Lublin, Radziwiłłowska 13, Lublin, Poland.
Ludmiła Grzybowska-SzatkowskaDepartment of Radiotherapy, Medical University of Lublin, Radziwiłłowska 13, Lublin, Poland.
Paweł CisekDepartment of Radiotherapy, Medical University of Lublin, Radziwiłłowska 13, Lublin, Poland.
Marta Ostrowska-LeśkoChair and Department of Toxicology, Medical University of Lublin, Jaczewskiego 8B, Lublin, Poland.
Jarosław DudkaChair and Department of Toxicology, Medical University of Lublin, Jaczewskiego 8B, Lublin, Poland.
Joanna KubikIndependent Medical Biology Unit, Medical University of Lublin, Jaczewskiego 8B, Lublin, Poland.
Jacek OsuchowskiChair and Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Jaczewskiego 8B, Lublin, Poland.
Paweł SzmyginChair and Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Jaczewskiego 8B, Lublin, Poland.
Bożena JaroszChair and Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Jaczewskiego 8B, Lublin, Poland.
Andrzej KrajkaInstitute of Computer Science, Maria Curie-Sklodowska University, Lublin, Poland.
Tomasz KrajkaDivision of Mathematics, Department of Production Computerisation and Robotisation, Mechanical Engineering Faculty, Lublin University of Technology, Nadbystrzycka 36, Lublin, Poland.
Kazimierz SzatkowskiFaculty of Management, Lublin University of Technology, Nadbystrzycka 38D, Lublin, Poland.
Brygida ŚlaskaInstitute of Biological Bases of Animal Production, University of Life Sciences in Lublin, Akademicka 13, Lublin, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Brain gliomas are among the tumors with the worst prognosis, and their incidence is increasing. Postoperative temozolomide-based chemoradiotherapy for grades 3 and 4 gliomas extended overall survival (OS) by approximately two months. An increasing number of clinical trials are investigating molecular-based therapy. Recent studies have demonstrated the involvement of Golgi apparatus proteins, including MYO18A (myosin-18A), in processes associated with abnormal proliferation, migration, apoptosis evasion, and angiogenesis promotion. The aim of this study was to investigate whether MYO18A has prognostic value in patients treated for brain gliomas. Methods: The research material in the work included tumor samples taken during neurosurgery and blood samples from 45 patients treated for brain gliomas with grade of 1 to 4 according to WHO, which were used to determine the expression of Results: This study showed higher Conclusion: The level of expression of

Indexed as

Biomarkers, TumorBrain NeoplasmsGliomaMyosinsAdultAgedFemaleHumansMaleMiddle AgedNeoplasm GradingPrognosisProgression-Free SurvivalBiomarkers, TumorMyosinsbrain gliomasGolgi apparatusmRNAMYO18A—myosin-18A

Identifiers

PMID42065053
PMCPMC13126409

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.